NeuroSense Therapeutics plans to showcase PARADIGM program results at NEALS 2026, detailing how clinical and biomarker evidence is shaping the Phase 3 development path for its lead candidate, PrimeC.
NeuroSense is positioning its lead drug candidate, PrimeC, for Phase 3 development by leveraging integrated clinical and biomarker data derived from the PARADIGM program. The upcoming presentation at the NEALS 2026 conference serves as a critical update for investors regarding the company's clinical development strategy and the refinement of its regulatory pathway.
It provides a platform for NeuroSense to share how PARADIGM program data is shaping the clinical strategy for the PARAGON Phase 3 development of PrimeC.
The company is focused on utilizing biomarker and clinical evidence to advance PrimeC through the PARAGON Phase 3 development program.
NeuroSense Therapeutics announced it will present integrated clinical and biomarker findings from its PARADIGM program at the upcoming NEALS 2026 conference. The data will provide critical insights into the Phase 3 development strategy for the company's lead drug candidate, PrimeC.
The presentation will provide essential clinical and biomarker evidence from the PARADIGM program, which directly informs the Phase 3 development strategy for the company's lead drug candidate, PrimeC.